Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + anlotinib for advanced or metastatic anaplastic thyroid cancer
ChiCTR2200067045Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in anaplastic thyroid cancer (ATC), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoints: objective response rate, disease control rate and 3 more. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on ChiCTR2200067045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067045.